Mechanisms of glucocorticoid-induced insulin resistance: Focus on adipose tissue function and lipid metabolism

Endocrinology and Metabolism Clinics of North America

Volumn 43, Issue 1, 2014, Pages 75-102

  Geer, Eliza B ^a   Islam, Julie ^b   Buettner, Christoph ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Adipose tissue; Cushing syndrome; Glucocorticoids; Insulin resistance; Lipids; Lipolysis

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ADIPONECTIN; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 1;

ABDOMINAL OBESITY; ADIPOSE TISSUE; BROWN ADIPOSE TISSUE; CHRONIC STRESS; CUSHING SYNDROME; ENERGY BALANCE; FATTY LIVER; GLUCONEOGENESIS; GLUCOSE UTILIZATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; LONG TERM EXPOSURE; PRIORITY JOURNAL; REVIEW; WHITE ADIPOSE TISSUE; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ADIPOSE TISSUE; GLUCOCORTICOIDS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM;

EID: 84896849509     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2013.10.005     Document Type: Review

References (215)

1. Geer E.B., Shen W., Gallagher D., et al. MRI assessment of lean and adipose tissue distribution in female patients with Cushing's disease. Clin Endocrinol (Oxf) 2010, 73(4):469-475.
2. Geer E.B., Shen W., Strohmayer E., et al. Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI. JClin Endocrinol Metab 2012, 97(5):1702-1711.
3. van Staa T.P., Leufkens H.G., Abenhaim L., et al. Use of oral corticosteroids in the United Kingdom. QJM 2000, 93(2):105-111.
4. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. JClin Endocrinol Metab 2004, 89(6):2548-2556.
5. Eckel R.H., Kahn R., Robertson R.M., et al. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 2006, 113(25):2943-2946.
6. Ridker P.M., Buring J.E., Cook N.R., et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003, 107(3):391-397.
7. Girman C.J., Rhodes T., Mercuri M., et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004, 93(2):136-141.
8. Solymoss B.C., Bourassa M.G., Campeau L., et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 2004, 93(2):159-164.
9. Etxabe J., Vazquez J.A. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994, 40(4):479-484.
10. Hauner H., Schmid P., Pfeiffer E.F. Glucocorticoids and insulin promote the differentiation of human adipocyte precursor cells into fat cells. JClin Endocrinol Metab 1987, 64(4):832-835.
11. Campbell J.E., Peckett A.J., D'Souza A.M., et al. Adipogenic and lipolytic effects of chronic glucocorticoid exposure. Am J Physiol Cell Physiol 2011, 300(1):C198-C209.
12. Slavin B.G., Ong J.M., Kern P.A. Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes. JLipid Res 1994, 35(9):1535-1541.
13. Samra J.S., Clark M.L., Humphreys S.M., et al. Effects of physiological hypercortisolemia on the regulation of lipolysis in subcutaneous adipose tissue. JClin Endocrinol Metab 1998, 83(2):626-631.
14. Djurhuus C.B., Gravholt C.H., Nielsen S., et al. Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. Am J Physiol Endocrinol Metab 2004, 286(3):E488-E494.
15. Lee M.J., Fried S.K. Glucocorticoids antagonize tumor necrosis factor-alpha-stimulated lipolysis and resistance to the antilipolytic effect of insulin in human adipocytes. Am J Physiol Endocrinol Metab 2012, 303(9):E1126-E1133.
16. Villena J.A., Roy S., Sarkadi-Nagy E., et al. Desnutrin, an adipocyte gene encoding a novel patatin domain-containing protein, is induced by fasting and glucocorticoids: ectopic expression of desnutrin increases triglyceride hydrolysis. JBiol Chem 2004, 279(45):47066-47075.
17. Gao Z., Zhang X., Zuberi A., et al. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol Endocrinol 2004, 18(8):2024-2034.
18. Lee M.J., Fried S.K., Mundt S.S., et al. Depot-specific regulation of the conversion of cortisone to cortisol in human adipose tissue. Obesity (Silver Spring) 2008, 16(6):1178-1185.
19. Rebuffe-Scrive M., Krotkiewski M., Elfverson J., et al. Muscle and adipose tissue morphology and metabolism in Cushing's syndrome. JClin Endocrinol Metab 1988, 67(6):1122-1128.
20. Krsek M., Rosicka M., Nedvidkova J., et al. Increased lipolysis of subcutaneous abdominal adipose tissue and altered noradrenergic activity in patients with Cushing's syndrome: an in-vivo microdialysis study. Physiol Res 2006, 55(4):421-428.
21. Diraison F., Dusserre E., Vidal H., et al. Increased hepatic lipogenesis but decreased expression of lipogenic gene in adipose tissue in human obesity. Am J Physiol Endocrinol Metab 2002, 282(1):E46-E51.
22. Roberts R., Hodson L., Dennis A.L., et al. Markers of de novo lipogenesis in adipose tissue: associations with small adipocytes and insulin sensitivity in humans. Diabetologia 2009, 52(5):882-890.
23. Mayas M.D., Ortega F.J., Macias-Gonzalez M., et al. Inverse relation between FASN expression in human adipose tissue and the insulin resistance level. Nutr Metab (Lond) 2010, 7:3.
24. Eissing L., Scherer T., Todter K., et al. De novo lipogenesis in human fat and liver is linked to ChREBP-beta and metabolic health. Nat Commun 2013, 4:1528.
25. Gathercole L.L., Morgan S.A., Bujalska I.J., et al. Regulation of lipogenesis by glucocorticoids and insulin in human adipose tissue. PLoS One 2011, 6(10):e26223.
26. Postic C., Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. JClin Invest 2008, 118(3):829-838.
27. Gathercole L.L., Bujalska I.J., Stewart P.M., et al. Glucocorticoid modulation of insulin signaling in human subcutaneous adipose tissue. JClin Endocrinol Metab 2007, 92(11):4332-4339.
28. Tomlinson J.J., Boudreau A., Wu D., et al. Insulin sensitization of human preadipocytes through glucocorticoid hormone induction of forkhead transcription factors. Mol Endocrinol 2010, 24(1):104-113.
29. Gathercole L.L., Morgan S.A., Bujalska I.J., et al. Short- and long-term glucocorticoid treatment enhances insulin signalling in human subcutaneous adipose tissue. Nutr Diabetes 2011, 1:e3.
30. Hazlehurst J.M., Gathercole L.L., Nasiri M., et al. Glucocorticoids fail to cause insulin resistance in human subcutaneous adipose tissue invivo. JClin Endocrinol Metab 2013, 98(4):1631-1640.
31. Buren J., Liu H.X., Jensen J., et al. Dexamethasone impairs insulin signalling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes. Eur J Endocrinol 2002, 146(3):419-429.
32. Lundgren M., Buren J., Ruge T., et al. Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes. JClin Endocrinol Metab 2004, 89(6):2989-2997.
33. Sakoda H., Ogihara T., Anai M., et al. Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Diabetes 2000, 49(10):1700-1708.
34. Baxter J.D., Forsham P.H. Tissue effects of glucocorticoids. Am J Med 1972, 53(5):573-589.
35. Donahue R.P., Abbott R.D. Central obesity and coronary heart disease in men. Lancet 1987, 2(8569):1215.
36. Despres J.P., Lemieux I., Bergeron J., et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008, 28(6):1039-1049.
37. Lean M.E., Han T.S., Seidell J.C. Impairment of health and quality of life in people with large waist circumference. Lancet 1998, 351(9106):853-856.
38. Chan J.M., Rimm E.B., Colditz G.A., et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994, 17(9):961-969.
39. Carey D.G., Jenkins A.B., Campbell L.V., et al. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996, 45(5):633-638.
40. Kissebah A.H., Krakower G.R. Regional adiposity and morbidity. Physiol Rev 1994, 74(4):761-811.
41. Ducluzeau P.H., Manchec-Poilblanc P., Roullier V., et al. Distribution of abdominal adipose tissue as a predictor of hepatic steatosis assessed by MRI. Clin Radiol 2010, 65(9):695-700.
42. Barahona M.J., Sucunza N., Resmini E., et al. Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. JClin Endocrinol Metab 2009, 94(9):3365-3371.
43. Mayo-Smith W., Hayes C.W., Biller B.M., et al. Body fat distribution measured with CT: correlations in healthy subjects, patients with anorexia nervosa, and patients with Cushing syndrome. Radiology 1989, 170(2):515-518.
44. Garrapa G.G., Pantanetti P., Arnaldi G., et al. Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome. JClin Endocrinol Metab 2001, 86(11):5301-5306.
45. Schafroth U., Godang K., Ueland T., et al. Leptin levels in relation to body composition and insulin concentration in patients with endogenous Cushing's syndrome compared to controls matched for body mass index. JEndocrinol Invest 2000, 23(6):349-355.
46. Wajchenberg B.L., Bosco A., Marone M.M., et al. Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease. JClin Endocrinol Metab 1995, 80(9):2791-2794.
47. Burt M.G., Gibney J., Ho K.K. Characterization of the metabolic phenotypes of Cushing's syndrome and growth hormone deficiency: a study of body composition and energy metabolism. Clin Endocrinol (Oxf) 2006, 64(4):436-443.
48. Burt M.G., Gibney J., Ho K.K. Protein metabolism in glucocorticoid excess: study in Cushing's syndrome and the effect of treatment. Am J Physiol Endocrinol Metab 2007, 292(5):E1426-E1432.
49. Rockall A.G., Sohaib S.A., Evans D., et al. Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome. Eur J Endocrinol 2003, 149(6):561-567.
50. Calao A., Pivonello R., Spiezia S., et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. JClin Endocrinol Metab 1999, 84:2664-2672.
51. Faggiano A., Pivonello R., Spiezia S., et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. JClin Endocrinol Metab 2003, 88:2527-2533.
52. Pivonello R., Faggiano A., Lombardi G., et al. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am 2005, 34(2):327-339. viii.
53. Lambert J.K., Goldberg L., Fayngold S., et al. Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients. JClin Endocrinol Metab 2013, 98(3):1022-1030.
54. Masuzaki H., Paterson J., Shinyama H., et al. Atransgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294(5549):2166-2170.
55. Veilleux A., Rheaume C., Daris M., et al. Omental adipose tissue type 1 11 beta-hydroxysteroid dehydrogenase oxoreductase activity, body fat distribution, and metabolic alterations in women. JClin Endocrinol Metab 2009, 94(9):3550-3557.
56. Varma V., Yao-Borengasser A., Bodles A.M., et al. Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance. Diabetes 2008, 57(2):432-439.
57. Spencer M., Yao-Borengasser A., Unal R., et al. Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab 2010, 299(6):E1016-E1027.
58. Pasarica M., Gowronska-Kozak B., Burk D., et al. Adipose tissue collagen VI in obesity. JClin Endocrinol Metab 2009, 94(12):5155-5162.
59. Spencer M., Unal R., Zhu B., et al. Adipose tissue extracellular matrix and vascular abnormalities in obesity and insulin resistance. JClin Endocrinol Metab 2011, 96(12):E1990-E1998.
60. Papaspyrou-Rao S., Schneider S.H., Petersen R.N., et al. Dexamethasone increases leptin expression in humans invivo. JClin Endocrinol Metab 1997, 82(5):1635-1637.
61. Masuzaki H., Ogawa Y., Hosoda K., et al. Glucocorticoid regulation of leptin synthesis and secretion in humans: elevated plasma leptin levels in Cushing's syndrome. JClin Endocrinol Metab 1997, 82(8):2542-2547.
62. Hube F., Lietz U., Igel M., et al. Difference in leptin mRNA levels between omental and subcutaneous abdominal adipose tissue from obese humans. Horm Metab Res 1996, 28(12):690-693.
63. Aso Y., Yamamoto R., Wakabayashi S., et al. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 2006, 55(7):1954-1960.
64. Heidemann C., Sun Q., van Dam R.M., et al. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 2008, 149(5):307-316.
65. Fasshauer M., Klein J., Neumann S., et al. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002, 290(3):1084-1089.
66. Paschke L., Zemleduch T., Rucinski M., et al. Adiponectin and adiponectin receptor system in the rat adrenal gland: ontogenetic and physiologic regulation, and its involvement in regulating adrenocortical growth and steroidogenesis. Peptides 2010, 31(9):1715-1724.
67. Bruun J.M., Lihn A.S., Madan A.K., et al. Higher production of IL-8 in visceral vs. subcutaneous adipose tissue. Implication of nonadipose cells in adipose tissue. Am J Physiol Endocrinol Metab 2004, 286(1):E8-E13.
68. Fried S.K., Bunkin D.A., Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. JClin Endocrinol Metab 1998, 83(3):847-850.
69. Trujillo M.E., Scherer P.E. Adipose tissue-derived factors: impact on health and disease. Endocr Rev 2006, 27(7):762-778.
70. Weisberg S.P., McCann D., Desai M., et al. Obesity is associated with macrophage accumulation in adipose tissue. JClin Invest 2003, 112(12):1796-1808.
71. Wang L., Liu J., Zhang A., et al. BVT.2733, a selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and inflammation in diet-induced obese mice. PLoS One 2012, 7(7):e40056.
72. Cannon B., Nedergaard J. Developmental biology: neither fat nor flesh. Nature 2008, 454(7207):947-948.
73. Almind K., Manieri M., Sivitz W.I., et al. Ectopic brown adipose tissue in muscle provides a mechanism for differences in risk of metabolic syndrome in mice. Proc Natl Acad Sci USA 2007, 104(7):2366-2371.
74. Tateishi K., Okada Y., Kallin E.M., et al. Role of Jhdm2a in regulating metabolic gene expression and obesity resistance. Nature 2009, 458(7239):757-761.
75. Cypess A.M., Lehman S., Williams G., et al. Identification and importance of brown adipose tissue in adult humans. NEngl J Med 2009, 360(15):1509-1517.
76. van Marken Lichtenbelt W.D., Vanhommerig J.W., Smulders N.M., et al. Cold-activated brown adipose tissue in healthy men. NEngl J Med 2009, 360(15):1500-1508.
77. Virtanen K.A., Lidell M.E., Orava J., et al. Functional brown adipose tissue in healthy adults. NEngl J Med 2009, 360(15):1518-1525.
78. Liu J., Kong X., Wang L., et al. Essential roles of 11beta-HSD1 in regulating brown adipocyte function. JMol Endocrinol 2013, 50(1):103-113.
79. Morgan S.A., Sherlock M., Gathercole L.L., et al. 11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 2009, 58(11):2506-2515.
80. Lim S., Son K.R., Song I.C., et al. Fat in liver/muscle correlates more strongly with insulin sensitivity in rats than abdominal fat. Obesity (Silver Spring) 2009, 17(1):188-195.
81. Greco A.V., Mingrone G., Giancaterini A., et al. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 2002, 51(1):144-151.
82. Jacob S., Machann J., Rett K., et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 1999, 48(5):1113-1119.
83. Misra A., Sinha S., Kumar M., et al. Proton magnetic resonance spectroscopy study of soleus muscle in non-obese healthy and Type 2 diabetic Asian Northern Indian males: high intramyocellular lipid content correlates with excess body fat and abdominal obesity. Diabet Med 2003, 20(5):361-367.
84. 13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999, 48(8):1600-1606.
85. Morino K., Petersen K.F., Shulman G.I. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006, 55(Suppl 2):S9-S15.
86. Morgan S.A., Gathercole L.L., Simonet C., et al. Regulation of lipid metabolism by glucocorticoids and 11beta-HSD1 in skeletal muscle. Endocrinology 2013, 154(7):2374-2384.
87. Goodpaster B.H., Thaete F.L., Kelley D.E. Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am J Clin Nutr 2000, 71(4):885-892.
88. Fabbrini E., Magkos F., Mohammed B.S., et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009, 106(36):15430-15435.
89. Amatruda J.M., Danahy S.A., Chang C.L. The effects of glucocorticoids on insulin-stimulated lipogenesis in primary cultures of rat hepatocytes. Biochem J 1983, 212(1):135-141.
90. Zhao L.F., Iwasaki Y., Zhe W., et al. Hormonal regulation of acetyl-CoA carboxylase isoenzyme gene transcription. Endocr J 2010, 57(4):317-324.
91. Dolinsky V.W., Douglas D.N., Lehner R., et al. Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone. Biochem J 2004, 378(Pt 3):967-974.
92. Schwarz J.M., Linfoot P., Dare D., et al. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003, 77(1):43-50.
93. Lemke U., Krones-Herzig A., Berriel Diaz M., et al. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab 2008, 8(3):212-223.
94. Zoppini G., Targher G., Venturi C., et al. Relationship of nonalcoholic hepatic steatosis to overnight low-dose dexamethasone suppression test in obese individuals. Clin Endocrinol (Oxf) 2004, 61(6):711-715.
95. Ahmed A., Rabbitt E., Brady T., et al. Aswitch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease. PLoS One 2012, 7(2):e29531.
96. Westerbacka J., Yki-Jarvinen H., Vehkavaara S., et al. Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. JClin Endocrinol Metab 2003, 88(10):4924-4931.
97. Targher G., Bertolini L., Zoppini G., et al. Relationship of non-alcoholic hepatic steatosis to cortisol secretion in diet-controlled Type 2 diabetic patients. Diabet Med 2005, 22(9):1146-1150.
98. Rockall A.G., Sohaib S.A., Evans D., et al. Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography. Eur J Endocrinol 2003, 149(6):543-548.
99. Dourakis S.P., Sevastianos V.A., Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol 2002, 97(4):1074-1075.
100. Nanki T., Koike R., Miyasaka N. Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosus. Am J Gastroenterol 1999, 94(11):3379.
101. Choi H.K., Seeger J.D. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005, 53(4):528-535.
102. Wang X., Magkos F., Patterson B.W., et al. Low-dose dexamethasone administration for 3 weeks favorably affects plasma HDL concentration and composition but does not affect very low-density lipoprotein kinetics. Eur J Endocrinol 2012, 167(2):217-223.
103. Filipsson H., Monson J.P., Koltowska-Haggstrom M., et al. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. JClin Endocrinol Metab 2006, 91(10):3954-3961.
104. Berg A.L., Nilsson-Ehle P. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney Int 1996, 50(2):538-542.
105. Berg A.L., Hansson P., Nilsson-Ehle P. ACTH 1-24 decreases hepatic lipase activities and low density lipoprotein concentrations in healthy men. JIntern Med 1991, 229(2):201-203.
106. Berg A.L., Nilsson-Ehle P. Direct effects of corticotropin on plasma lipoprotein metabolism in man-studies invivo and invitro. Metabolism 1994, 43(1):90-97.
107. Arnaldi G., Angeli A., Atkinson A.B., et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. JClin Endocrinol Metab 2003, 88(12):5593-5602.
108. Giordano R., Picu A., Marinazzo E., et al. Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol 2011, 75(3):354-360.
109. Mancini T., Kola B., Mantero F., et al. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004, 61(6):768-777.
110. Moisan M.P., Seckl J.R., Edwards C.R. 11 beta-hydroxysteroid dehydrogenase bioactivity and messenger RNA expression in rat forebrain: localization in hypothalamus, hippocampus, and cortex. Endocrinology 1990, 127(3):1450-1455.
111. Lakshmi V., Sakai R.R., McEwen B.S., et al. Regional distribution of 11 beta-hydroxysteroid dehydrogenase in rat brain. Endocrinology 1991, 128(4):1741-1748.
112. Seckl J.R., Dow R.C., Low S.C., et al. The 11 beta-hydroxysteroid dehydrogenase inhibitor glycyrrhetinic acid affects corticosteroid feedback regulation of hypothalamic corticotrophin-releasing peptides in rats. JEndocrinol 1993, 136(3):471-477.
113. Bisschop P.H., Dekker M.J., Osterthun W., et al. Expression of 11beta-hydroxysteroid dehydrogenase type 1 in the human hypothalamus. JNeuroendocrinol 2013, 25(5):425-432.
114. Zakrzewska K.E., Cusin I., Stricker-Krongrad A., et al. Induction of obesity and hyperleptinemia by central glucocorticoid infusion in the rat. Diabetes 1999, 48(2):365-370.
115. Asensio C., Muzzin P., Rohner-Jeanrenaud F. Role of glucocorticoids in the physiopathology of excessive fat deposition and insulin resistance. Int J Obes Relat Metab Disord 2004, 28(Suppl 4):S45-S52.
116. Cusin I., Rouru J., Rohner-Jeanrenaud F. Intracerebroventricular glucocorticoid infusion in normal rats: induction of parasympathetic-mediated obesity and insulin resistance. Obes Res 2001, 9(7):401-406.
117. Yi C.X., Foppen E., Abplanalp W., et al. Glucocorticoid signaling in the arcuate nucleus modulates hepatic insulin sensitivity. Diabetes 2012, 61(2):339-345.
118. Kuo L.E., Kitlinska J.B., Tilan J.U., et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007, 13(7):803-811.
119. Kola B., Christ-Crain M., Lolli F., et al. Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. JClin Endocrinol Metab 2008, 93(12):4969-4973.
120. Kola B., Boscaro M., Rutter G.A., et al. Expanding role of AMPK in endocrinology. Trends Endocrinol Metab 2006, 17(5):205-215.
121. Gauthier M.S., O'Brien E.L., Bigornia S., et al. Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans. Biochem Biophys Res Commun 2011, 404(1):382-387.
122. Christ-Crain M., Kola B., Lolli F., et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J 2008, 22(6):1672-1683.
123. Butler H., Korbonits M. Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. Eur J Endocrinol 2009, 161(5):655-662.
124. Cota D., Marsicano G., Tschop M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. JClin Invest 2003, 112(3):423-431.
125. Di S., Malcher-Lopes R., Halmos K.C., et al. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. JNeurosci 2003, 23(12):4850-4857.
126. Di S., Malcher-Lopes R., Marcheselli V.L., et al. Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 2005, 146(10):4292-4301.
127. Scerif M., Fuzesi T., Thomas J.D., et al. CB1 receptor mediates the effects of glucocorticoids on AMPK activity in the hypothalamus. JEndocrinol 2013, 219(1):79-88.
128. Scherer T., Buettner C. The dysregulation of the endocannabinoid system in diabesity-a tricky problem. JMol Med (Berl) 2009, 87(7):663-668.
129. Tomlinson J.W., Walker E.A., Bujalska I.J., et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004, 25(5):831-866.
130. Rask E., Olsson T., Soderberg S., et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. JClin Endocrinol Metab 2001, 86(3):1418-1421.
131. Engeli S., Bohnke J., Feldpausch M., et al. Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res 2004, 12(1):9-17.
132. Paulsen S.K., Pedersen S.B., Fisker S., et al. 11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring) 2007, 15(8):1954-1960.
133. Anagnostis P., Athyros V.G., Tziomalos K., et al. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. JClin Endocrinol Metab 2009, 94(8):2692-2701.
134. Bujalska I.J., Kumar S., Stewart P.M. Does central obesity reflect "Cushing's disease of the omentum"?. Lancet 1997, 349(9060):1210-1213.
135. Stimson R.H., Andersson J., Andrew R., et al. Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans. Diabetes 2009, 58(1):46-53.
136. Morton N.M., Seckl J.R. 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 2008, 36:146-164.
137. Bujalska I.J., Gathercole L.L., Tomlinson J.W., et al. Anovel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. JEndocrinol 2008, 197(2):297-307.
138. Kotelevtsev Y., Holmes M.C., Burchell A., et al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997, 94(26):14924-14929.
139. Holmes M.C., Kotelevtsev Y., Mullins J.J., et al. Phenotypic analysis of mice bearing targeted deletions of 11beta-hydroxysteroid dehydrogenases 1 and 2 genes. Mol Cell Endocrinol 2001, 171(1-2):15-20.
140. Alberts P., Engblom L., Edling N., et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002, 45(11):1528-1532.
141. Morton N.M., Paterson J.M., Masuzaki H., et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004, 53(4):931-938.
142. Bujalska I.J., Kumar S., Hewison M., et al. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase. Endocrinology 1999, 140(7):3188-3196.
143. Basu R., Basu A., Grudzien M., et al. Liver is the site of splanchnic cortisol production in obese nondiabetic humans. Diabetes 2009, 58(1):39-45.
144. Lavery G.G., Zielinska A.E., Gathercole L.L., et al. Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11beta-hydroxysteroid dehydrogenase type 1. Endocrinology 2012, 153(7):3236-3248.
145. Masuzaki H., Yamamoto H., Kenyon C.J., et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. JClin Invest 2003, 112(1):83-90.
146. Paterson J.M., Morton N.M., Fievet C., et al. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 2004, 101(18):7088-7093.
147. Morton N.M., Densmore V., Wamil M., et al. Apolygenic model of the metabolic syndrome with reduced circulating and intra-adipose glucocorticoid action. Diabetes 2005, 54(12):3371-3378.
148. Stewart P.M., Tomlinson J.W. Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both?. Diabetes 2009, 58(1):14-15.
149. Harno E., Cottrell E.C., Keevil B.G., et al. 11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11beta-HSD1 is knocked out in livers of male mice. Endocrinology 2013, 154(10):3599-3609.
150. Rask E., Walker B.R., Soderberg S., et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. JClin Endocrinol Metab 2002, 87(7):3330-3336.
151. Mariniello B., Ronconi V., Rilli S., et al. Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. Eur J Endocrinol 2006, 155(3):435-441.
152. Paulmyer-Lacroix O., Boullu S., Oliver C., et al. Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. JClin Endocrinol Metab 2002, 87(6):2701-2705.
153. Tomlinson J.W., Moore J.S., Clark P.M., et al. Weight loss increases 11beta-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. JClin Endocrinol Metab 2004, 89(6):2711-2716.
154. Basu R., Singh R.J., Basu A., et al. Obesity and type 2 diabetes do not alter splanchnic cortisol production in humans. JClin Endocrinol Metab 2005, 90(7):3919-3926.
155. Tomlinson J.W., Sinha B., Bujalska I., et al. Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. JClin Endocrinol Metab 2002, 87(12):5630-5635.
156. Valsamakis G., Anwar A., Tomlinson J.W., et al. 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. JClin Endocrinol Metab 2004, 89(9):4755-4761.
157. Kerstens M.N., Riemens S.C., Sluiter W.J., et al. Lack of relationship between 11beta-hydroxysteroid dehydrogenase setpoint and insulin sensitivity in the basal state and after 24h of insulin infusion in healthy subjects and type 2 diabetic patients. Clin Endocrinol (Oxf) 2000, 52(4):403-411.
158. Purnell J.Q., Kahn S.E., Samuels M.H., et al. Enhanced cortisol production rates, free cortisol, and 11beta-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss. Am J Physiol Endocrinol Metab 2009, 296(2):E351-E357.
159. Alberti L., Girola A., Gilardini L., et al. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects. Int J Obes (Lond) 2007, 31(12):1826-1831.
160. Uckaya G., Karadurmus N., Kutlu O., et al. Adipose tissue 11-beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase gene expressions are increased in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008, 82(Suppl 2):S135-S140.
161. Tomlinson J.W., Finney J., Gay C., et al. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. Diabetes 2008, 57(10):2652-2660.
162. Stewart P.M., Boulton A., Kumar S., et al. Cortisol metabolism in human obesity: impaired cortisone→cortisol conversion in subjects with central adiposity. JClin Endocrinol Metab 1999, 84(3):1022-1027.
163. Lindsay R.S., Wake D.J., Nair S., et al. Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. JClin Endocrinol Metab 2003, 88(6):2738-2744.
164. Tomlinson J.W., Moore J., Cooper M.S., et al. Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 2001, 142(5):1982-1989.
165. Espindola-Antunes D., Kater C.E. Adipose tissue expression of 11beta-hydroxysteroid dehydrogenase type 1 in Cushing's syndrome and in obesity. Arq Bras Endocrinol Metabol 2007, 51(8):1397-1403.
166. Walker B.R., Connacher A.A., Lindsay R.M., et al. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. JClin Endocrinol Metab 1995, 80(11):3155-3159.
167. Andrews R.C., Rooyackers O., Walker B.R. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. JClin Endocrinol Metab 2003, 88(1):285-291.
168. Tomlinson J.W., Sherlock M., Hughes B., et al. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity invivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. JClin Endocrinol Metab 2007, 92(3):857-864.
169. Barf T., Vallgarda J., Emond R., et al. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. JMed Chem 2002, 45(18):3813-3815.
170. Hermanowski-Vosatka A., Balkovec J.M., Cheng K., et al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. JExp Med 2005, 202(4):517-527.
171. Sundbom M., Kaiser C., Bjorkstrand E., et al. Inhibition of 11betaHSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice. BMC Pharmacol 2008, 8:3.
172. Berthiaume M., Laplante M., Festuccia W., et al. Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1. Endocrinology 2007, 148(5):2391-2397.
173. Berthiaume M., Laplante M., Festuccia W.T., et al. 11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues. Am J Physiol Endocrinol Metab 2007, 293(4):E1045-E1052.
174. Berthiaume M., Laplante M., Festuccia W.T., et al. Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats. Int J Obes (Lond) 2009, 33(5):601-604.
175. Edgerton D.S., Basu R., Ramnanan C.J., et al. Effect of 11 beta-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog. Am J Physiol Endocrinol Metab 2010, 298(5):E1019-E1026.
176. Rosenstock J., Banarer S., Fonseca V.A., et al. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010, 33(7):1516-1522.
177. Feig P.U., Shah S., Hermanowski-Vosatka A., et al. Effects of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab 2011, 13(6):498-504.
178. Shah S., Hermanowski-Vosatka A., Gibson K., et al. Efficacy and safety of the selective 11beta-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. JAm Soc Hypertens 2011, 5(3):166-176.
179. Abrahams L., Semjonous N.M., Guest P., et al. Biomarkers of hypothalamic-pituitary-adrenal axis activity in mice lacking 11beta-HSD1 and H6PDH. JEndocrinol 2012, 214(3):367-372.
180. Pasquali R., Ambrosi B., Armanini D., et al. Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose-response study. JClin Endocrinol Metab 2002, 87(1):166-175.
181. Mattsson C., Reynolds R.M., Simonyte K., et al. Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men. JClin Endocrinol Metab 2009, 94(4):1347-1352.
182. Vicennati V., Pasquali R. Abnormalities of the hypothalamic-pituitary-adrenal axis in nondepressed women with abdominal obesity and relations with insulin resistance: evidence for a central and a peripheral alteration. JClin Endocrinol Metab 2000, 85(11):4093-4098.
183. Lottenberg S.A., Giannella-Neto D., Derendorf H., et al. Effect of fat distribution on the pharmacokinetics of cortisol in obesity. Int J Clin Pharmacol Ther 1998, 36(9):501-505.
184. Korbonits M., Trainer P.J., Nelson M.L., et al. Differential stimulation of cortisol and dehydroepiandrosterone levels by food in obese and normal subjects: relation to body fat distribution. Clin Endocrinol 1996, 45(6):699-706.
185. Pasquali R., Anconetani B., Chattat R., et al. Hypothalamic-pituitary-adrenal axis activity and its relationship to the autonomic nervous system in women with visceral and subcutaneous obesity: effects of the corticotropin-releasing factor/arginine-vasopressin test and of stress. Metabolism 1996, 45(3):351-356.
186. Fraser R., Ingram M.C., Anderson N.H., et al. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 1999, 33(6):1364-1368.
187. Marin P., Darin N., Amemiya T., et al. Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism 1992, 41(8):882-886.
188. Pasquali R., Biscotti D., Spinucci G., et al. Pulsatile secretion of ACTH and cortisol in premenopausal women: effect of obesity and body fat distribution. Clin Endocrinol (Oxf) 1998, 48(5):603-612.
189. Adam E.K., Doane L.D., Zinbarg R.E., et al. Prospective prediction of major depressive disorder from cortisol awakening responses in adolescence. Psychoneuroendocrinology 2010, 35(6):921-931.
190. Adam T.C., Hasson R.E., Ventura E.E., et al. Cortisol is negatively associated with insulin sensitivity in overweight Latino youth. JClin Endocrinol Metab 2010, 95(10):4729-4735.
191. Otte C., Wust S., Zhao S., et al. Glucocorticoid receptor gene, low-grade inflammation, and heart failure: the Heart and Soul study. JClin Endocrinol Metab 2010, 95(6):2885-2891.
192. Manenschijn L., van den Akker E.L., Lamberts S.W., et al. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann N Y Acad Sci 2009, 1179:179-198.
193. Geelen C.C., van Greevenbroek M.M., van Rossum E.F., et al. BclI glucocorticoid receptor polymorphism is associated with greater body fatness: the Hoorn and CODAM studies. JClin Endocrinol Metab 2013, 98(3):E595-E599.
194. Epel E.S., McEwen B., Seeman T., et al. Stress and body shape: stress-induced cortisol secretion is consistently greater among women with central fat. Psychosom Med 2000, 62(5):623-632.
195. Pasquali R., Vicennati V. Activity of the hypothalamic-pituitary-adrenal axis in different obesity phenotypes. Int J Obes Relat Metab Disord 2000, 24(Suppl 2):S47-S49.
196. Manenschijn L., Schaap L., van Schoor N.M., et al. High long-term cortisol levels, measured in scalp hair, are associated with a history of cardiovascular disease. JClin Endocrinol Metab 2013, 98(5):2078-2083.
197. Stalder T., Kirschbaum C., Alexander N., et al. Cortisol in hair and the metabolic syndrome. JClin Endocrinol Metab 2013, 98(6):2573-2580.
198. Huizenga N.A., Koper J.W., de Lange P., et al. Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. JClin Endocrinol Metab 1998, 83(1):47-54.
199. Xu H., Barnes G.T., Yang Q., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. JClin Invest 2003, 112(12):1821-1830.
200. Large V., Reynisdottir S., Langin D., et al. Decreased expression and function of adipocyte hormone-sensitive lipase in subcutaneous fat cells of obese subjects. JLipid Res 1999, 40(11):2059-2066.
201. Cawthorn W.P., Sethi J.K. TNF-alpha and adipocyte biology. FEBS Lett 2008, 582(1):117-131.
202. Borst S.E. The role of TNF-alpha in insulin resistance. Endocrine 2004, 23(2-3):177-182.
203. Kosteli A., Sugaru E., Haemmerle G., et al. Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. JClin Invest 2010, 120(10):3466-3479.
204. Capel F., Klimcakova E., Viguerie N., et al. Macrophages and adipocytes in human obesity: adipose tissue gene expression and insulin sensitivity during calorie restriction and weight stabilization. Diabetes 2009, 58(7):1558-1567.
205. Waage A., Bakke O. Glucocorticoids suppress the production of tumour necrosis factor by lipopolysaccharide-stimulated human monocytes. Immunology 1988, 63(2):299-302.
206. Udono-Fujimori R., Totsune K., Murakami O., et al. Suppression of cytokine-induced expression of endothelin-1 by dexamethasone in human retinal pigment epithelial cells. JCardiovasc Pharmacol 2004, 44:S471-S473.
207. Pereda M.P., Lohrer P., Kovalovsky D., et al. Interleukin-6 is inhibited by glucocorticoids and stimulates ACTH secretion and POMC expression in human corticotroph pituitary adenomas. Exp Clin Endocrinol Diabetes 2000, 108:202-207.
208. Barber A.E., Coyle S.M., Marano M.A., et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. JImmunol 1993, 150(5):1999-2006.
209. DeRijk R., Michelson D., Karp B., et al. Exercise and circadian rhythm-induced variations in plasma cortisol differentially regulate interleukin-1 beta (IL-1 beta), IL-6, and tumor necrosis factor-alpha (TNF alpha) production in humans: high sensitivity of TNF alpha and resistance of IL-6. JClin Endocrinol Metab 1997, 82(7):2182-2191.
210. Lionakis M.S., Kontoyiannis D.P. Glucocorticoids and invasive fungal infections. Lancet 2003, 362(9398):1828-1838.
211. Rajala M.W., Scherer P.E. Minireview: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003, 144(9):3765-3773.
212. Trayhurn P., Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004, 92(3):347-355.
213. Papanicolaou D.A., Tsigos C., Oldfield E.H., et al. Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of steroid withdrawal syndrome and adrenal insufficiency?. JClin Endocrinol Metab 1996, 81:2303-2306.
214. Setola E., Losa M., Lanzi R., et al. Increased insulin-stimulated endothelin-1 release is a distinct vascular phenotype distinguishing Cushing's disease from metabolic syndrome. Clin Endocrinol 2007, 66:586-592.
215. Ueland T., Kristo C., Godang K., et al. Interleukin-1 receptor antagonist is associated with fat distribution in endogenous Cushing's syndrome: a longitudinal study. JClin Endocrinol Metab 2003, 88:1492-1496.